Cancer IVD market forecast to reach $19.85B by 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Cancer In Vitro Diagnostics (IVD) Market In 2026 And 2030?
The cancer in vitro diagnostics (ivd) market has experienced robust expansion over recent years. Its valuation is projected to increase from $14.32 billion in 2025 to $15.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this expansion has been driven by factors such as the broadening of hospital diagnostic infrastructure, the rise in biomarker-based testing, the integration of PCR and immunoassay technologies, the increase in cancer screening initiatives, and advancements in laboratory automation.
The cancer in vitro diagnostics (IVD) market size is projected to experience robust expansion over the coming years. By 2030, this market is anticipated to reach a valuation of $19.85 billion, exhibiting a compound annual growth rate (CAGR) of 6.7%. Factors driving this growth during the projected timeframe include the escalating demand for personalized oncology diagnostics, increased funding for genomic sequencing, the broadening scope of point-of-care cancer testing, the expanding adoption of cloud-based diagnostic platforms, and a heightened emphasis on precision medicine. Key trends anticipated during the forecast period encompass the wider embrace of molecular and genomic cancer testing, the growing application of companion diagnostics, the increasing incorporation of AI-driven data analysis, the broadening utility of liquid biopsy applications, and an intensified focus on identifying cancer at earlier stages.
Access Your Free Sample Report For In-Depth Market Analysis:
What Significant Factors Are Influencing The Cancer In Vitro Diagnostics (IVD) Market Expansion?
The growing occurrence of cancer is projected to fuel the expansion of the cancer in vitro diagnostics (IVD) market moving forward. Cancer is characterized by the uncontrolled proliferation and spread of abnormal cells within the body, which can invade adjacent tissues and form tumors. The escalating incidence of cancer stems from an aging populace, where increased life expectancy and reduced mortality from infectious diseases result in more elderly individuals facing a higher risk of developing cancer. Cancer in vitro diagnostics (IVD) contributes to cancer management by enabling early and precise detection, continuous monitoring, and effective treatment of the disease through laboratory tests conducted on patient samples, thereby facilitating timely therapeutic decisions and enhancing patient outcomes. For example, in January 2023, the American Cancer Society, a US-based professional organization dedicated to eradicating cancer, reported that 1,958,310 new cancer cases and 609,820 cancer deaths are expected in 2023 in the United States. Hence, the rising incidence of cancer is a primary catalyst for the growth of the cancer in vitro diagnostics (IVD) market.
Which Segment Classifications Are Used In The Cancer In Vitro Diagnostics (IVD) Market Segment Analysis?
The cancer in vitro diagnostics (ivd) market covered in this report is segmented –
1) By Product Type: Reagents And Kits, Instruments, Software And Services
2) By Technology: Clinical Chemistry, Immunochemistry Or Immunoassays, Hematology, Coagulation And Hemostasis, Cytogenetics Or Liquid Biopsy Technologies, Molecular Diagnostics, Other Technology
3) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer
4) By End-Users: Hospitals, Laboratories, Academics, Point-Of-Care Testing, Specialty Oncology Diagnostic Centers, Other End Users
Subsegments:
1) By Reagents And Kits: PCR Reagents And Kits, NGS Reagents And Kits, Immunoassay Reagents And Kits, In Situ Hybridization (ISH) Reagents And Kits, Others
2) By Instruments: PCR Instruments, NGS Instruments, Immunoassay Analyzers, ISH Instruments, Others
3) By Software And Services: Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, Support And Maintenance Services
What Trends Are Affecting The Direction Of The Cancer In Vitro Diagnostics (IVD) Market?
Leading companies within the cancer in vitro diagnostics market are concentrating on innovations in cancer screening, such as blood-based colorectal cancer (CRC) screening, to deliver convenient, non-invasive, and accurate early detection of the disease. Blood-based CRC screening involves identifying cancer-associated molecular alterations, like circulating tumor DNA (ctDNA), within a patient’s blood sample to detect colorectal cancer in individuals at average risk. For instance, in July 2024, Guardant Health, Inc., a U.S.-based precision oncology company, secured U.S. Food and Drug Administration (FDA) approval for its Guardant Shield blood test as a primary colorectal cancer screening option. This test functions by analyzing a blood sample for specific ctDNA methylation patterns and other tumor-derived markers; its unique features include noninvasive collection, high analytical accuracy, and integration with clinical workflows for primary screening; its applications cover colorectal cancer early detection in average-risk adults; and its benefits encompass improved patient adherence, earlier detection of malignancy, a potential reduction in late-stage diagnoses, and eligibility for Medicare reimbursement, which enables broader population access to screening.
Which Firms Are Contributing To The Cancer In Vitro Diagnostics (IVD) Market Ecosystem?
Major companies operating in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., Illumina Inc., Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., Tulip Diagnostics Pvt Ltd., Guardant Health Inc., Agilent Technologies Inc., BGI Genomics
Get The Full Cancer In Vitro Diagnostics (IVD) Market Report:
Which Region Leads The Cancer In Vitro Diagnostics (IVD) Market In Terms Of Market Share?
North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cancer In Vitro Diagnostics (IVD) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Cancer In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company
Hydraulic Pumps Market Report 2026
https://www.thebusinessresearchcompany.com/report/hydraulic-pumps-global-market-report
Hydraulics Market Report 2026
https://www.thebusinessresearchcompany.com/report/hydraulics-global-market-report
Smart Elevators Market Report 2026
https://www.thebusinessresearchcompany.com/report/smart-elevators-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
